Accelerate to discover

Back to filter

Related topics

Responsive fluorescence probe for detection of Hypochlorous acid in live cells and animals

Spectral Instruments Imaging

Jan 17, 2019

In this work, a new fluorescence probe, PQI, was developed for monitoring of the HOCl level in biological samples. The...

Improved differentiation of Retinal Organoids stem cells derived using rotating-wall vessels

Synthecon

Jan 15, 2019

Pluripotent stem cells can be differentiated into 3D retinal organoids, with major cell types self-patterning into a...

IncuCyte webinar recording: CAR T-cell therapy, frontiers in cancer Immunotherapy

Sartorius

Jan 11, 2019

The success of immune checkpoint blockade adds new therapeutic category to Cancers are the most heterogenous group of...

CT‐analyzer plug‐ins: ROI shrink‐wrap and primitive ROI

Bruker Biospin

Jan 7, 2019

The ROI shrink‐wrap gives the possibility to automatically generate a region‐of‐interest by adapting to the shape of...

Jan 23, 2019

ACEA Biosciences launch xCELLigence RTCA software Pro for immunotherapy applications

Acea Biosciences

Dec 28, 2018

RTCA Software Pro is an integrated software package for running and analyzing real time cell analysis data from...

Cellular stress induces erythrocyte assembly and promotes microangiopathy

Fluxion Biosciences

Dec 19, 2018

Microangiopathy with subsequent organ damage represents a major complication in several diseases. The mechanisms...

The need for ultra high field magnetic resonance imaging

Bruker Biospin

Dec 17, 2018

MRI  is a noninvasive imaging technology that is known for its superior soft tissue contrast and ability to provide...

Jan 23, 2019

Live-cell labeling of endogenous proteins with nanometer precision by transduced nanobodies

Etaluma

Dec 6, 2018

Accurate labeling of endogenous proteins for advanced light microscopy in living cells remains challenging. Nanobodies...

Show all topics (10)

Heterodimeric compounds with dual-targeting active against both HIV and tuberculosis.

Jun 4, 2018

Both HIV and Tuberculosis are considered to be one of the most dangerous infectious diseases in the world. Quite often these two pathogens work in synchrony, making the risk of patient´s death twice as high. To solve this problem researchers from the Engelhardt Institute of Molecular biology in Russia cooperated with the National Institute of Health in the USA. They created compounds with dual activity against both pathogens by creating a heterodimer based on nucleosides. These heterodimers have two active components with two different rates of release based on the speed of their hydrolysis. They tested five of such compounds on HIV and Tuberculosis strain MS-114, which is drug-resistance. Drug-resistance of tuberculosis is one of the main problems in the treatment nowadays.

The compounds were judged based on the ability to inhibit these pathogens. Additionally, a testing on the host tissue was done using NovoCyte. The researchers tested the viability of mammalian lymphoid tissue after treatment. The results show that the heterodimers are non-toxic and non-static towards the cells while maintaining the potency against the pathogens. So far the compound was tested in vivo and ex vitro and seem to be a very promising solution. These results bring interesting insight and novel approach toward treatment of both HIV and Tuberculosis.

Want to know more?

Scientific paper
Application

Related technologies: Conventional flow cytometry

Brand profile

Acea Biosciences

ACEA manufactures xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.

Related products

The best in class personalized flow cytometer

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey